Eli Lilly along with VIR and GSK Report Results of Bamlanivimab + VIR-7831 in P-II BLAZE-4 Study for Low-Risk Adults with COVID

March 30, 2021 Auto Bot bamlanivimab, Clinical Trials, Eli Lilly, GSK, Study, Vir, VIR-7831 0

Shots:

  • The P-II BLAZE-4 study involves assessing bamlanivimab as monothx. and bamlanivimab (700mg) + VIR-7831 (500mg) vs PBO in 1000 participants with symptomatic low-risk COVID-19 in the outpatient setting across the US and Puerto Rico
  • Results: The dual regimen met its 1EPs i.e. 70% relative reduction in persistently high viral load (> 5.27; cycle threshold value < 27.5) @day7. Additionally, it showed a reduction in the key virologic 2EPs of mean change from baseline to days 3, 5 and 7 in SARS-CoV-2 viral load
  • The preclinical data suggested that the administration of Bamlanivimab + VIR-7831 together may provide protection against current variants of SARS-CoV-2 that are resistant to bamlanivimab

Click here to­ read full press release/ article | Ref: GSK | Image: The New York Times

The post Eli Lilly along with VIR and GSK Report Results of Bamlanivimab + VIR-7831 in P-II BLAZE-4 Study for Low-Risk Adults with COVID first appeared on PharmaShots.